Balyasny Asset Management
AKBA icon

Balyasny Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Balyasny Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,154
Closed -$33.3K – 2865
2025
Q2 		$33.3K Sell
9,154
-1,236,340
-99% -$3.4M ﹤0.01% 2712
2025
Q1 		$2.39M Buy
1,245,494
+971,042
+354% +$1.98M ﹤0.01% 1623
2024
Q4 		$521K Buy
+274,452
New +$477K ﹤0.01% 2182
2024
Q3 		– Sell
-129,896
Closed -$132K – 2700
2024
Q2 		$132K Sell
129,896
-48,897
-27% -$60.4K ﹤0.01% 2383
2024
Q1 		$327K Buy
+178,793
New +$286K ﹤0.01% 2225
2022
Q4 		– Sell
-40,606
Closed -$13K – 2739
2022
Q3 		$13K Buy
40,606
+15,972
+65% +$6.27K ﹤0.01% 2622
2022
Q2 		$9K Buy
+24,634
New +$10.3K ﹤0.01% 2597
2020
Q4 		– Sell
-18,947
Closed -$48K – 1280
2020
Q3 		$48K Buy
+18,947
New +$166K ﹤0.01% 1241
2018
Q3 		– Sell
-12,645
Closed -$126K – 1629
2018
Q2 		$126K Sell
12,645
-20,454
-62% -$205K ﹤0.01% 1693
2018
Q1 		$315K Buy
33,099
+21,050
+175% +$294K ﹤0.01% 1596
2017
Q4 		$179K Buy
+12,049
New +$200K ﹤0.01% 1929
2015
Q3 		– Sell
-828,357
Closed -$8.52M – 1127
2015
Q2 		$8.52M Buy
828,357
+689,681
+497% +$5.88M 0.05% 441
2015
Q1 		$1.54M Sell
138,676
-90,258
-39% -$961K 0.01% 658
2014
Q4 		$2.67M Buy
+228,934
New +$3.28M 0.02% 526

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Balyasny Asset Management's AKBA Position: Q3 2025 in Review

Balyasny Asset Management sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 9,154 shares — an estimated $33.3K sold.

Balyasny Asset Management first reported a position in AKBA in Q4 2014 and held it in 14 quarters. The position peaked at $8.52M in Q2 2015. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Balyasny Asset Management reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 9,154 Akebia Therapeutics shares in Q3 2025, an estimated $33.3K.
  • Balyasny Asset Management first reported a position in Akebia Therapeutics in Q4 2014 and held it in 14 quarters.
  • Balyasny Asset Management's Akebia Therapeutics position peaked at $8.52M in Q2 2015.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.